Patent ID: 6150342
Filing Date: 2000-11-21
Classification: A61K,A61P,C08B

Abstract:
A method for treatment of angina pectoris by administration of a heparin derivative from bovine or porcine heparin characterised by:having a molecular weight equal to or larger than standard bovine or porcine heparin,showing a sulfur content which is equal to or higher than that of said bovine or porcine heparin,having an anticoagulant activity in the anti-FXa assay of less than 10% of said bovine or porcine heparin it was made from,showing a ratio of APTT activity over anti-FXa activity of 3-35, showing a reduced prolongation of bleeding time compared to said bovine or porcine heparin it was made from as measured in the rat tail after i.v. administration, andshowing enhancement of the rate of development of coronary collaterals in dogs equal to or better than clinically used heparin, in a therapeutic dose to a patient in need of said treatment.